Dr. Jorge J. Nieva, MD

Dr. Nieva practices at USC Norris Cancer Hospital in Los Angeles, California.

Dr. Nieva's NPI, 1497717672, was assigned on April 4, 2006. Dr. Nieva graduated from UC Irvine School of Medicine in 1997. Dr. Nieva holds California license A67649.

Dr. Nieva's primary practice is USC Norris Cancer Hospital, at 1441 Eastlake Ave, Los Angeles, CA.

Dr. Nieva's primary practice is USC Norris Cancer Hospital in Los Angeles, California. Dr. Nieva is also affiliated with Los Angeles General Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Nieva to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nieva practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nieva's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nieva is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Nieva's licenses on file in 3 states: California, Montana and Wyoming.

Dmand AI lists chronic leukemia, deep vein thrombosis (DVT), fluid and electrolyte imbalances, lung cancer, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Nieva treats.

CMS data shows 755 Medicare services from Dr. Nieva across 9 procedure codes in 2024, for 189 Medicare patients. Medicare paid $47,486 for them.

CMS counts 189 Medicare patients who saw Dr. Nieva in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have cancer, and 75% have high blood pressure. 46% are also on Medicaid. Their average risk score is 3.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nieva's median patient age at 70, with 40% women.

In 2024, Dr. Nieva wrote 434 Medicare Part D claims for 87 patients. 67% of them were for generic drugs. CMS names the drug for 207 of them, across 10 drugs with 11 or more claims each, at $1,325,271 in total drug cost. In 2023, CMS named 166 claims across 9 drugs.

Dr. Nieva accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nieva as offering telehealth.

Dmand AI links 10 papers to Dr. Nieva, published from 2012 to 2021. 2012 was the busiest year, with 3. Dr. Nieva's most frequent co-authors are Lyudmila A. Bazhenova, MD, Kelly J. Bethel, MD and Afshin Dowlati, MD.

Dmand AI links Dr. Nieva to 9 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Leukoplakia. University of Southern California sponsors the most, 4.

CMS Open Payments shows 167 general payments to Dr. Nieva from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. AstraZeneca Pharmaceuticals LP paid the most, $17,717. It also lists 4 research payments totaling $3,999 from 2020 to 2025.

Dr. Nieva graduated from UC Irvine School of Medicine in 1997. Dr. Nieva is a member of AACR and ASCO.

Dr. Nieva is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.